Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements

Cancer Genetics and Cytogenetics

Volumn 182, Issue 2, 2008, Pages 111-115

  De Melo, Valeria A S ^a   Milojkovic, Dragana ^a   Marin, David ^a   Apperley, Jane F ^a   Nacheva, Elisabeth P ^b   Reid, Alistair G ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ABL1 GENE; ARTICLE; BCR GENE; CHROMOSOME 22Q; CHROMOSOME 9Q; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA STRAND BREAKAGE; GENE DELETION; GENE FUSION; GENE REARRANGEMENT; GENE SEQUENCE; GENE TRANSLOCATION; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL;

CHROMOSOME BREAKAGE; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; CYTOGENETIC ANALYSIS; GENE DELETION; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-BCR; TRANSLOCATION, GENETIC;

EID: 41749115965     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2008.01.007     Document Type: Article

References (16)

1. Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. [Letter]. Nature 243 (1973) 290-293
2. Melo J.V., and Barnes D.J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7 (2007) 441-453
3. Reid A.G., Huntly B.J., Grace C., Green A.R., and Nacheva E.P. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol 121 (2003) 419-427
4. Hagemeijer A., de Klein A., Gödde-Salz E., Turc-Carel C., Smit E.M., van Agthoven A.J., and Grosveld G.C. Translocation of c-abl to "masked" Ph in chronic myeloid leukemia. Cancer Genet Cytogenet 18 (1985) 95-104
5. Sinclair P.B., Nacheva E.P., Leversha M., Telford N., Chang J., Reid A., Bench A., Champion K., Huntly B., and Green A.R. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95 (2000) 738-743
6. Huntly B.J., Reid A.G., Bench A.J., Campbell L.J., Telford N., Shepherd P., Szer J., Prince H.M., Turner P., Grace C., Nacheva E.P., and Green A.R. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98 (2001) 1732-1738
7. Kolomietz E., Al-Maghrabi J., Brennan S., Karaskova J., Minkin S., Lipton J., and Squire J.A. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 97 (2001) 3581-3588
8. Huntly B.J., Guilhot F., Reid A.G., Vassiliou G., Hennig E., Franke C., Byrne J., Brizard A., Niederwieser D., Freeman-Edward J., Cuthbert G., Bown N., Clark R.E., Nacheva E.P., Green A.R., and Deininger M.W. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 102 (2003) 2205-2212
9. Quintas-Cardama A., Kantarjian H., Talpaz M., O'Brien S., Garcia-Manero G., Verstovsek S., Rios M.B., Hayes K., Glassman A., Bekele B.N., Zhou X., and Cortes J. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 105 (2005) 2281-2286
10. Kreil S., Pfirrmann M., Haferlach C., Waghorn K., Chase A., Hehlmann R., Reiter A., Hochhaus A., and Cross N.C. German Chronic Myelogenous Leukemia (CML) Study Group. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 110 (2007) 1283-1290
11. Hagemeijer A., Buijs A., Smit E., Janssen B., Creemers G.J., Van der Plas D., and Grosveld G. Translocation of BCR to chromosome 9: a new cytogenetic variant detected by FISH in two Ph-negative, BCR-positive patients with chronic myeloid leukemia. Genes Chromosomes Cancer 8 (1993) 237-245
12. Nacheva E., Holloway T., Brown K., Bloxham D., and Green A.R. Philadelphia-negative chronic myeloid leukaemia: detection by FISH of BCR-ABL fusion gene localized either to chromosome 9 or chromosome 22. Br J Haematol 87 (1994) 409-412
13. Cohen N., Rozenfeld-Granot G., Hardan I., Brok-Simoni F., Amariglio N., Rechavi G., and Trakhtenbrot L. Subgroup of patients with Philadelphia positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 128 (2001) 114-119
14. Fourouclas N., Campbell P.J., Bench A.J., Swanton S., Baxter E.J., Huntly B.J., and Green A.R. Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia. Haematologica 91 (2006) 952-955
15. Zagaria A., Anelli L., Albano F., Storlazzi C.T., Liso A., Roberti M.G., Buquicchio C., Liso V., Rocchi M., and Specchia G. A fluorescence in situ hybridization study of complex t(9;22) in two chronic myelocytic leukemia cases with a masked Philadelphia chromosome. Cancer Genet Cytogenet 150 (2004) 81-85
16. Cohen N., Amariglio N., Rechavi G., Trakhtenbrot L., and Hardan I. Simultaneous detection of deletions of 9q and 22q in a subgroup of chronic myelocytic leukemia Philadelphia-positive patients by a novel probe. Cancer Genet Cytogenet 141 (2003) 89-90